These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 37703723)

  • 1. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
    Bai Q; Wang J; Zhou X
    Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.
    Hu M; Zhong C; Wang J; Chen J; Zhou T
    Front Immunol; 2024; 15():1399975. PubMed ID: 38774882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
    Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
    Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [EGFR Exon 20 Insertion Mutation: Research Status and New Treatment Strategies].
    Tian M; Wang N; Dou Z; Song X; Zhang X
    Zhongguo Fei Ai Za Zhi; 2024 Aug; 27(8):579-592. PubMed ID: 39318251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting
    Liu H; Qin J; Qian X
    Cancer Control; 2024; 31():10732748241292782. PubMed ID: 39417568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advances in Treatment of Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations].
    Yang X; Zhao J
    Zhongguo Fei Ai Za Zhi; 2022 May; 25(5):337-350. PubMed ID: 35599009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the Diagnosis and Treatment of Advanced Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.
    Liu J; Xiang Y; Fang T; Zeng L; Sun A; Lin Y; Lu K
    Clin Lung Cancer; 2024 Mar; 25(2):100-108. PubMed ID: 38172024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
    Hernandez L; Young M
    J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluating the Clinical Characteristics and Prognosis of Advanced Non-Small Cell Lung Cancer with Exon 20 Insertions.
    Wang H; Xu Y; Lin J; Huang Y
    Cancer Control; 2024; 31():10732748241262190. PubMed ID: 38857163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer.
    Park S; Park S; Kim TM; Kim S; Koh J; Lim J; Yi K; Yi B; Ju YS; Kim M; Keam B; Kim JS; Jeon YK; Kim DW; Kim YT; Heo DS
    Eur J Cancer; 2024 Sep; 208():114206. PubMed ID: 38981315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
    Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer.
    Seo D; Lim JH
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review.
    Watanabe N; Horio Y; Fujiwara Y
    Ann Transl Med; 2022 Dec; 10(23):1283. PubMed ID: 36618815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
    Remon J; Hendriks LEL; Cardona AF; Besse B
    Cancer Treat Rev; 2020 Nov; 90():102105. PubMed ID: 32979839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options.
    Brazel D; Kroening G; Nagasaka M
    BioDrugs; 2022 Nov; 36(6):717-729. PubMed ID: 36255589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-small cell lung cancer with
    Kwon CS; Lin HM; Crossland V; Churchill EN; Curran E; Forsythe A; Tomaras D; Ou SI
    Curr Med Res Opin; 2022 Aug; 38(8):1341-1350. PubMed ID: 35621011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress in Detection of EGFR Exon 20 Insertion Mutation and Targeted Therapies 
in Non-small Cell Lung Cancer].
    Wang Y; Chu T
    Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):135-147. PubMed ID: 36872052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Yang GJ; Li J; Xu HY; Sun Y; Liu L; Li HS; Yang L; Zhang Y; Li GH; Wang Y
    Lung Cancer; 2021 Feb; 152():39-48. PubMed ID: 33341538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives.
    Boch T; Köhler J; Janning M; Loges S
    Cancer Biol Med; 2022 Dec; 19(11):1543-64. PubMed ID: 36476337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
    Yoh K; Azuma K; Hayashi H; Nishio M; Chikamori K; Ichihara E; Watanabe Y; Asato T; Kitagawa T; Fram RJ; Ohe Y
    Int J Clin Oncol; 2024 Oct; 29(10):1461-1474. PubMed ID: 39190099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.